BIOINVENT INTERNATIONAL AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.2 SEK | -0.85% |
|
+7.91% | +22.36% |
| Sales 2024 * | 63.6M 5.85M | Sales 2025 * | 1.2B 111M | Capitalization | 1.54B 142M |
|---|---|---|---|---|---|
| Net income 2024 * | -964M -88.74M | Net income 2025 * | 580M 53.39M | EV / Sales 2024 * | 19.2 x |
| Net cash position 2024 * | 320M 29.41M | Net cash position 2025 * | 1.49B 137M | EV / Sales 2025 * | 0.04 x |
| P/E ratio 2024 * |
-5.96
x | P/E ratio 2025 * |
2.4
x | Employees | 111 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.64% |
More Fundamentals
* Assessed data
More news
Latest transcript on BioInvent International AB
More press releases
| 1 day | -1.07% | ||
| 1 week | +8.14% | ||
| Current month | +36.76% | ||
| 1 month | +38.56% | ||
| 3 months | +40.91% | ||
| 6 months | +52.56% | ||
| Current year | +22.63% |
1 week
21.60
24.50
1 month
16.5024.50
Current year
15.0024.50
1 year
14.0029.90
3 years
14.0061.40
5 years
14.0063.00
10 years
14.00106.00
| Managers | Title | Age | Since |
|---|---|---|---|
Martin Welschof
CEO | Chief Executive Officer | 63 | 18-08-31 |
Stefan Ericsson
DFI | Director of Finance/CFO | 61 | 97-12-31 |
Marie Moores
COO | Chief Operating Officer | - | 22-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bernd Seizinger
BRD | Director/Board Member | 67 | 17-12-31 |
Leonard Kruimer
CHM | Chairman | 66 | 16-05-11 |
Vincent Ossipow
BRD | Director/Board Member | 55 | 16-05-11 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 23.2 | -0.85% | 55 571 |
| 24-04-23 | 23.4 | +0.43% | 32,774 |
| 24-04-22 | 23.3 | -1.69% | 74,301 |
| 24-04-19 | 23.7 | -1.04% | 111,372 |
| 24-04-18 | 23.95 | +11.40% | 293,089 |
Delayed Quote Nasdaq Stockholm, April 24, 2024 at 10:09 am EDT
More quotes
BioInvent International AB is a Sweden-based biopharmaceutical company, that develops antibody-based drugs for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of haematological cancer and solid tumors. The Companyâs operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The Company has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.
Calendar
02:00am
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
23.4
SEK
Average target price
83
SEK
Spread / Average Target
+254.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +22.63% | 142M | |
| -0.47% | 105B | |
| +4.24% | 97.5B | |
| +1.63% | 22.19B | |
| -15.25% | 21.33B | |
| -7.63% | 18.68B | |
| -41.41% | 16.6B | |
| -19.90% | 14.52B | |
| +6.91% | 14.09B | |
| +22.89% | 10.99B |
- Stock Market
- Equities
- BINV Stock
